These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9656100)

  • 1. Free-to-total prostate specific antigen ratio in clinical staging of prostate cancer.
    Maeda H; Arai Y; Ishitoya S; Okubo K; Aoki Y; Okada T; Maekawa S
    Hinyokika Kiyo; 1998 May; 44(5):307-11. PubMed ID: 9656100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
    Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative prediction of final pathological features is not improved by the free-to-total prostate-specific antigen ratio in Japanese men with clinically localized prostate cancer.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Feb; 12(2):182-6. PubMed ID: 15733113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
    Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
    Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
    Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of NIH-IV prostatitis on free and free-to-total PSA.
    Stancik I; Lüftenegger W; Klimpfinger M; Müller MM; Hoeltl W
    Eur Urol; 2004 Dec; 46(6):760-4. PubMed ID: 15548444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prediction of the stage of patients with prostate cancer by the combination of serum prostate specific antigen and Gleason score].
    Song G; Zhou LQ; He ZS; Li NC; Li M; Hao JR; Pan BN; Na YQ
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):376-8. PubMed ID: 16638345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    J Urol; 1997 Feb; 157(2):544-7. PubMed ID: 8996352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen.
    van Iersel MP; Witjes WP; Thomas CM; Segers MF; Oosterhof GO; Debruyne FM
    Prostate Suppl; 1996; 7():48-57. PubMed ID: 8950364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer].
    Han G; Gao JP; Cao XL; Hong BF; Tang J
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):379-81. PubMed ID: 16638346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
    Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma.
    Froschermaier SE; Pilarsky CP; Wirth MP
    Urology; 1996 Apr; 47(4):525-8. PubMed ID: 8638361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Free/total prostate specific antigen ratio (%PSA) to predict probability of prostate cancer].
    Zenimoto M; Kita M; Arai T; Murayama T; Mori M
    Rinsho Byori; 2003 Oct; 51(10):969-73. PubMed ID: 14653195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW; Liu G; Sheng BW
    Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
    Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.